The transition from relapsing-remitting MS to irreversible disability: clinical evaluation

被引:0
|
作者
M. Trojano
D. Paolicelli
A. Bellacosa
S. Cataldo
机构
[1] University of Bari,Department of Neurological and Psychiatric Sciences
来源
Neurological Sciences | 2003年 / 24卷
关键词
Multiple sclerosis; Disease duration; Prognosis; Age; Disability progression;
D O I
暂无
中图分类号
学科分类号
摘要
The development of a progressive course is by far the most deleterious event in the case of a multiple sclerosis (MS) patient. It occurs in about 90% of relapsing remitting patients by 20–25 years from onset. The clinical transition to secondary progressive MS is phenotypically distinctive and both patients and physicians acknowledge that a fundamental shift in the degree of responsiveness to anti-inflammatory therapies has occurred. This review discusses the clinical studies that provided important findings relating to our understanding on different mechanisms that may contribute to irreversible disability in MS.
引用
收藏
页码:s268 / s270
相关论文
共 50 条
  • [21] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Emma D. Deeks
    Drugs, 2016, 76 : 243 - 254
  • [22] Leptomeningeal Enhancement Kinetics In Relapsing-Remitting MS
    Tagge, I.
    Ontaneda, D.
    Sakaie, K.
    Butler, C. K.
    Powers, K.
    Woodward, W.
    Spain, R. I.
    Bourdette, D.
    Simon, J.
    Reich, D.
    Rooney, W.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 149 - 150
  • [23] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Blair, Hannah A.
    DRUGS, 2019, 79 (18) : 1965 - 1976
  • [24] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Deeks, Emma D.
    DRUGS, 2016, 76 (02) : 243 - 254
  • [25] Classifying silent progression in relapsing-remitting MS
    Filippi, Massimo
    Rocca, Maria A.
    NATURE REVIEWS NEUROLOGY, 2019, 15 (06) : 315 - 316
  • [26] Pregnancy protects against long-term disability accrual in relapsing-remitting MS
    Jokubaitis, V. G.
    Kalincik, T.
    Lorscheider, J.
    Spelman, T.
    Horakova, D.
    Duquette, P.
    Girard, M.
    Prat, A.
    Izquierdo, G.
    Grammond, P.
    Pucci, E.
    Grand'Maison, F.
    Granella, F.
    Sola, P.
    Bergamaschi, R.
    Iuliano, G.
    Spitaleri, D.
    Hodgkinson, S.
    Olascoaga, J.
    Verheul, F.
    McCombe, P.
    Rozsa, C.
    Lechner-Scott, J.
    Terzi, M.
    Hughes, S.
    Saladino, M. -L.
    Lugaresi, A.
    Trojano, M.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 120 - 122
  • [27] Parity and disability progression in relapsing-remitting multiple sclerosis
    Achiron, Anat
    Ben-David, Alon
    Gurevich, Michael
    Magalashvili, David
    Menascu, Shay
    Dolev, Mark
    Stern, Yael
    Ziv-Baran, Tomer
    JOURNAL OF NEUROLOGY, 2020, 267 (12) : 3753 - 3762
  • [28] Clinical characteristics of the response to β-interferon in relapsing-remitting Multiple Sclerosis from the Burgundy MS database
    Fromont, A
    Le Teuff, G
    Couvreur, G
    Dumas, R
    Giroud, M
    Quantin, C
    Moreau, T
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S238 - S238
  • [29] Clinical course before and after change of immunomodulating therapy in relapsing-remitting MS
    Khan, OA
    Caon, C
    Zvartau-Hind, M
    Din, MU
    Lisak, RP
    NEUROLOGY, 2001, 56 (08) : A355 - A355
  • [30] Correlation between functional MRI techniques and early disability in ambulatory patients with relapsing-remitting MS
    Mohamed, Al-Amir Bassiouny
    Algahalan, Hesham Abdelghani
    Thabit, Mohamed N.
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2022, 58 (01):